HC Wainwright & Co. reiterated coverage of Field Trip Health with a rating of Buy and set a new price target of $25.00 from $20.00 previously

HC Wainwright & Co. initiated coverage of Field Trip Health with a rating of Buy and set a new price target of $20.00

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

S-8 - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

SUPPL - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral Sciences at the School of Medicine at the University of Virginia, has joined its Scientific Advisory board. Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecu

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or "Reunion"), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "REUN" at the opening of the market on August 17, 2022. Trading of the Company's shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company's former subsidiary, Field Trip Health & Wellness Ltd. ("FTHW") into a stand-alone

Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

- Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN"- Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol "FTHW" - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022 - Field Trip Health & Wellness Ltd. completes $19.9 million private placement financing TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.) (TSX:FTRP, NASDAQ:FTRP) (the "Company"), and Field Trip Health &

TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc

– Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. – Field Trip Discovery to be renamed Reunion Neuroscience Inc., remaining listed on the NASDAQ Stock Market and Toronto Stock Exchange. TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip", the "Company"), a global leader in the development and delivery of psychedelic therapies, is pleased to announce that the TSX Venture Exchange (the "TSXV") has issued its conditional listing approval for the previously announced spinout transaction of its clinics business into Field Trip Health & Wellness Ltd

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio TORONTO, July 21, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today the first successful dosings in the Phase 1 Clinical Study entitled "A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers." The study is being conducted at PARC Clinical Research at

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement expected to occur in August.- Also announces closing of subscription receipt offering. TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip" or the "Corporation"), a global leader in the development and delivery of psychedelic therapies, today announces that on June 29, 2022, it received final court approval in respect of the previously announced spin-out of its clinics business to Field Trip Health & Wellness Ltd. ("Field Trip H&W") by way of plan of arrangement (the "Arrangeme

TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip" or "Corporation"), a global leader in the development and delivery of psychedelic therapies, today announced that on June 27, 2022, its shareholders approved both the Arrangement Resolution, the Concurrent Financing Resolution and the SpinCo Incentive Plan Resolution (each as defined in the Circular (each as defined below)) at its special meeting of shareholders (the "Meeting"), thereby approving the previously announced spin-out of its clinics business to Field Trip Health & Wellness Ltd. ("Field Trip H&W") by way of a plan of arrangement (the "Arrangement"). A total of 47.25%

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside chat at the H.C. Wainwright 1st Annual Mental Healthcare Conference taking place June 27, 2022. Date: June 27, 2022Time: 4:30 p.m. E.T.Location: New York City The fireside chat will be webcast live at 4:30 p.m. Eastern Time on Monday, June 27, through the following link: https://journey.ct.events/view/9a92c93f-2f82-4814-8d6a-22033c171e41.

Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi

TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Thursday, June 30, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13730739. A live webcast of the conference call can be accessed v

Transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Shareholders of Field Trip will receive shares of each company. Company to host a conference call on Friday, April 29, 2022 at 8:30 a.m. ET. TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) (the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisio

Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year.At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash and cash equivalents and short-term investments.Received Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT.Launched Site Management Organization Services ("SMO") and appointed Stéphan Côté as Head of Quality to lead the program which enables companies and researchers developing psychedelic therapies to use Field Trip's world class facilities, and expertly trained medical and therapy teams

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal third quarter ended December 31, 2021, after market close on Tuesday, February 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Wednesday, February 16, 2022 at 8:30am ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13726364. A live webcast of the conference call can be accessed via t

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the "FT-200 Group") and filed a provisional patent in connection to the composition of matter for the first molecule identified in the FT-200 Group.Continued to invest in best-in-class clinical infrastructure, with nine clinics currently in operation and nine locations under construction or about to commence construction.Commenced trading on the NASDAQ Global Select Market (

TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, November 16 at 8:30 am ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13724604. A live webcast of the conference call can be accessed via the Events

At June 30, 2021 had approximately $100 million in unrestricted cash and cash equivalents, funds held in trust and short-term investmentsDevelopment of FT-104, a novel psychedelic molecule with pending patents, continues to progress with GMP production achievedThe Company remains on track to meet milestone of 20 sites open or under construction by December 2021 TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021. All results are reported under International Financial Rep

Field Trip (NASDAQ:FTRP), Wesana (OTCQB:WSNAF), Braxia (OTC:BRAXF) and Irwin Naturals (OTC: IWINF) released their quarterly results. Field Trip Health & Wellness Ltd.  Psychedelic-assisted therapy provider Field Trip (TSXV:FTHW) reported its fiscal and business results for the three-month period ended June 30, 2022. The company recently split into two new public companies to separate drug development on one hand, and healthcare and wellness on the other: Field Trip Discovery and Field Trip Health, which are now called Reunion Neuroscience Inc. and Field Trip Health & Wellness (or Field Trip alone).  The latter’s financial results for the three months ended June 30, 2022 are the following

  GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 4.17% at $0.35 Cybin (AMEX:CYBN) shares closed up 1.94% at $0.77 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 1.92% at $4.77 Field Trip Health (NASDAQ:FTRP) shares closed up 1.07% at $0.84 LOSERS: GH Research (NASDAQ:GHRS) shares closed down 9.37% at $12.09 Allied (OTC:ALID) shares closed down 8.33% at $0.44 Seelos Therapeutics (NASDAQ:SEEL) shares closed down 5.28% at $0.92 Numinus Wellness (OTC:NUMIF) shares closed down 2.96% at $0.23 Compass Pathways (NASDAQ:CMPS) shares closed down 2.91% at $17.37 Mind Medicine (NASDAQ:MNMD) shares closed down 2.86% at $0.68 Biomind Labs (OTC:BMNDF) shares closed down 0.00

  GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.70% at $0.98 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.18% at $4.68 Revive Therapeutics (OTC:RVVTF) shares closed up 1.82% at $0.34 LOSERS: Allied (OTC:ALID) shares closed down 12.73% at $0.48 Cybin (AMEX:CYBN) shares closed down 6.21% at $0.75 Numinus Wellness (OTC:NUMIF) shares closed down 4.78% at $0.24 Mind Medicine (NASDAQ:MNMD) shares closed down 3.53% at $0.70 Compass Pathways (NASDAQ:CMPS) shares closed down 2.53% at $17.89 Field Trip Health (NASDAQ:FTRP) shares closed down 1.98% at $0.83 Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $0.75 GH Research (NASDAQ:GHRS) shares closed down 0.

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. • GreenPower Motor Co (NASDAQ:GP) is estimated to report quarterly loss at $0.15 per share on revenue of $5.59 million. • Mondee Hldgs (NASDAQ:MOND) is likely to report quarterly loss at $0.04 per share on revenue of $38.94 million. • Reshape Lifesciences (NASDAQ:RSLS) is expected to report quarterly loss at $0.35 per share on revenue of $3.41 million. • Alaunos Therapeutics (NASDAQ:TCRT) is expected to report earnings for its second quarter. • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $0.19 per share on revenue of $5.25 million. • IM Cannab

  GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 11.58% at $0.73 Numinus Wellness (OTC:NUMIF) shares closed up 11.53% at $0.25 Allied (OTC:ALID) shares closed up 7.84% at $0.55 Compass Pathways (NASDAQ:CMPS) shares closed up 5.91% at $18.36 GH Research (NASDAQ:GHRS) shares closed up 5.79% at $13.33 Seelos Therapeutics (NASDAQ:SEEL) shares closed up 4.79% at $0.95 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.39% at $4.58 Revive Therapeutics (OTC:RVVTF) shares closed up 3.13% at $0.33 LOSERS: Cybin (AMEX:CYBN) shares closed down 6.60% at $0.80 Field Trip Health (NASDAQ:FTRP) shares closed down 0.00% at $0.85 Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $

- Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN" - Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol “FTHW” - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022 - Field Trip Health & Wellness Ltd. completes $19.9 million private placement financing

  GAINERS: Allied (OTC:ALID) shares closed up 6.25% at $0.51 GH Research (NASDAQ:GHRS) shares closed up 2.19% at $12.60 Numinus Wellness (OTC:NUMIF) shares closed up 1.68% at $0.22 LOSERS: Compass Pathways (NASDAQ:CMPS) shares closed down 12.16% at $17.33 Revive Therapeutics (OTC:RVVTF) shares closed down 9.86% at $0.32 ATAI Life Sciences (NASDAQ:ATAI) shares closed down 5.34% at $4.43 Seelos Therapeutics (NASDAQ:SEEL) shares closed down 2.53% at $0.91 Mind Medicine (NASDAQ:MNMD) shares closed down 0.21% at $0.65 Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $0.75 Field Trip Health (NASDAQ:FTRP) shares closed down 0.58% at $0.85 Cybin (AMEX:CYBN) shares closed down 0

  GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 12.32% at $0.65 GH Research (NASDAQ:GHRS) shares closed up 10.02% at $12.74 Cybin (AMEX:CYBN) shares closed up 7.57% at $0.85 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 6.12% at $4.68 Seelos Therapeutics (NASDAQ:SEEL) shares closed up 4.52% at $0.93 Compass Pathways (NASDAQ:CMPS) shares closed up 4.17% at $19.73 Revive Therapeutics (OTC:RVVTF) shares closed up 1.43% at $0.35 Allied (OTC:ALID) shares closed up 1.05% at $0.48 LOSERS: Numinus Wellness (OTC:NUMIF) shares closed down 2.48% at $0.22 Field Trip Health (NASDAQ:FTRP) shares closed down 0.58% at $0.85 Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $

  GAINERS: Cybin (AMEX:CYBN) shares closed up 10.35% at $0.79 Field Trip Health (NASDAQ:FTRP) shares closed up 6.25% at $0.85 Allied (OTC:ALID) shares closed up 1.06% at $0.47   LOSERS: Numinus Wellness (OTC:NUMIF) shares closed down 5.09% at $0.23 Compass Pathways (NASDAQ:CMPS) shares closed down 3.56% at $18.94 GH Research (NASDAQ:GHRS) shares closed down 3.50% at $11.58 Revive Therapeutics (OTC:RVVTF) shares closed down 2.80% at $0.35 Mind Medicine (NASDAQ:MNMD) shares closed down 1.68% at $0.58 Seelos Therapeutics (NASDAQ:SEEL) shares closed down 1.16% at $0.89 ATAI Life Sciences (NASDAQ:ATAI) shares closed down 0.45% at $4.41 Biomind Labs (OTC:BMNDF) shares closed dow

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 29.83% at $15.80 Numinus Wellness (OTC:NUMIF) shares closed up 16.20% at $0.26 Cybin (AMEX:CYBN) shares closed up 14.94% at $0.71 Compass Pathways (NASDAQ:CMPS) shares closed up 14.69% at $20.07 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 6.57% at $4.38 Revive Therapeutics (OTC:RVVTF) shares closed up 4.63% at $0.36 Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.84% at $1.00 Field Trip Health (NASDAQ:FTRP) shares closed up 1.12% at $0.84 LOSERS: Mind Medicine (NASDAQ:MNMD) shares closed down 12.15% at $0.62 Allied (OTC:ALID) shares closed down 0.00% at $0.52 Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $